Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf209 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, 2025. Verfasst von Naoki Fukuda und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Carcinoma, Neuroendocrine, Thyroid Neoplasms, Pyrazoles. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Medullary thyroid carcinoma is a rare thyroid malignancy derived from parafollicular C cells that is frequently driven by activating mutations in the REarranged during Transfection (RET) proto-oncogene. While most actionable RET mutations are located in the extracellular cysteine-rich or intracellular tyrosine kinase domains, mutations in the transmembrane domain are exceedingly rare and their oncogenic significance remains unclear. We report a case of a 59-year-old male with sporadic medullary thyroid carcinoma harboring a rare RET A641R mutation in the transmembrane domain. The patient experienced multiple locoregional recurrences after four surgical resections. While the companion diagnostic test did not identify RET mutations, comprehensive genomic profiling using a next-generation sequencing panel revealed the RET A641R mutation. Following administration of selpercatinib, a selective RET inhibitor, a rapid biochemical response with decreased serum carcinoembryonic antigen and calcitonin levels was observed, and radiological assessment showed partial response. This is the first report demonstrating the clinical efficacy of selpercatinib in a patient with medullary thyroid carcinoma harboring a RET A641R mutation, supporting the oncogenic potential of this rare variant. This case also emphasizes the importance of comprehensive genomic profiling in identifying rare but actionable RET alterations that are undetectable by targeted sequencing companion diagnostic tests. Selpercatinib may represent an effective therapeutic option for patients with medullary thyroid carcinoma driven by uncommon RET mutations, including mutations in the transmembrane domain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Department of Clinical Cancer Genomics, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
- Department of Head and Neck Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Department of Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Division of Cancer Genomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
ORCID-Profile: Naoki Fukuda, Tomohiro Chiba, Ippei Fukada, Seiichi Mori, Jumpei Yoshida, Takehiro Nakao, Kenji Nakano, Makiko Ono, Kengo Takeuchi, Shunji Takahashi, Yuji Miura
Zitieren
APA
Fukuda, N., Toda, K., Chiba, T., Fukada, I., Mori, S., Tonooka, A., Toda, E., Yoshida, J., Wang, X., Oki, R., Nakao, T., Urasaki, T., Nakano, K., Ono, M., Tomomatsu, J., Takeuchi, K., Takahashi, S., & Miura, Y. (2025). Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib. The Oncologist. https://doi.org/10.1093/oncolo/oyaf209
Vancouver
Fukuda N, Toda K, Chiba T, Fukada I, Mori S, Tonooka A, et al. Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib. The Oncologist. 2025. doi:10.1093/oncolo/oyaf209
BibTeX
@article{Fukuda2025,
author = {Fukuda, Naoki and Toda, Kazuhisa and Chiba, Tomohiro and Fukada, Ippei and Mori, Seiichi and Tonooka, Akiko and Toda, Erisa and Yoshida, Jumpei and Wang, Xiaofei and Oki, Ryosuke and Nakao, Takehiro and Urasaki, Tetsuya and Nakano, Kenji and Ono, Makiko and Tomomatsu, Junichi and Takeuchi, Kengo and Takahashi, Shunji and Miura, Yuji},
title = {Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf209}
}
EUVIMED